Literature DB >> 11800284

Influence of type II 5' deiodinase on TSH content in diabetic rats.

C Aláez1, R Calvo, M J Obregón, C Alvarez, L Goya, F Escrivá, M A Martín, A M Pascual-Leone.   

Abstract

The influence of hypothalamic and pituitary type II 5'deiodinase (5'D-II) activities and T3 content on pituitary TSH content was investigated in streptozotocin (STZ)-induced diabetic rats (D). The results show, first, that hypothalamic and pituitary 5'D-II activities were lower in neonatal D rats versus control (C) rats, and the normal developmental pattern was altered. Secondly, when D and C rats were thyroidectomized (Tx) at 25 days of age (D+Tx, C+Tx), pituitary and hypothalamic 5'D-II activities increased ten days later in both populations vs. intact rats, but the percentage of increase was smaller in D+Tx than in C+Tx. The hypothalamic T3 to T4 ratios were also decreased in D+Tx animals (0.38) as compared to C+Tx rats (1.64). The hypothalamic T3 content was reduced by 30% in D as compared to C rats and by 80% in D+Tx as compared to C+Tx rats, showing a defect in hypothalamic T4 deiodination. Pituitary TSH content increased after Tx in D+Tx, but not in C+Tx. These results in diabetic rats indicate that the hypothalamic and pituitary 5'D-II activity and hypothalamic T3 content are affected by diabetes and play a role in the regulation of pituitary TSH content.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11800284     DOI: 10.1007/bf03179815

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  38 in total

Review 1.  Diabetes in the undernourished: coincidence or consequence?

Authors:  R H Rao
Journal:  Endocr Rev       Date:  1988-02       Impact factor: 19.871

Review 2.  Relationships between circulating and intracellular thyroid hormones: physiological and clinical implications.

Authors:  P R Larsen; J E Silva; M M Kaplan
Journal:  Endocr Rev       Date:  1981       Impact factor: 19.871

3.  An analysis of the sources and quantity of 3,5,3'-triiodothyronine specifically bound to nuclear receptors in rat cerebral cortex and cerebellum.

Authors:  F R Crantz; J E Silva; P R Larsen
Journal:  Endocrinology       Date:  1982-02       Impact factor: 4.736

4.  Early changes in thyroid hormone metabolism in the heart, liver, and brown adipose tissue during the induction of low T3 syndrome in streptozotocin-diabetic rats.

Authors:  L S Bjørn-Hansen Gøtzsche; O Gøtzsche; A Flyvbjerg; N Boye
Journal:  Acta Endocrinol (Copenh)       Date:  1990-07

5.  Evidence against a major role of L-thyroxine at the pituitary level: studies in rats treated with iopanoic acid (telepaque).

Authors:  M J Obregon; A Pascual; J Mallol; G Morreale de Escobar; F Escobar del Rey
Journal:  Endocrinology       Date:  1980-06       Impact factor: 4.736

6.  Impaired 3,5,3'-triiodothyronine (T3) production in diabetic patients.

Authors:  C S Pittman; A K Suda; J B Chambers; G Y Ray
Journal:  Metabolism       Date:  1979-04       Impact factor: 8.694

7.  Inhibition of intrapituitary thyroxine to 3.5.3'-triiodothyronine conversion prevents the acute suppression of thyrotropin release by thyroxine in hypothyroid rats.

Authors:  P R Larsen; T E Dick; B P Markovitz; M M Kaplan; T G Gard
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

8.  Effects of streptozocin-induced diabetes and food restriction on quantities and source of T4 and T3 in rat tissues.

Authors:  J P Schröder-van der Elst; D van der Heide
Journal:  Diabetes       Date:  1992-02       Impact factor: 9.461

9.  Effect of streptozotocin diabetes on the hypothalamic-pituitary-thyroid axis in the rat.

Authors:  C González; E Montoya; T Jolín
Journal:  Endocrinology       Date:  1980-12       Impact factor: 4.736

10.  Localization of thyrotropin-releasing hormone- and insulin-immunoreactivity in the pancreas of neonatal rats after injection of streptozotocin at birth.

Authors:  P Leduque; S Aratan-Spire; B Wolf; P M Dubois; P Czernichow
Journal:  Cell Tissue Res       Date:  1987-04       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.